CTI BioPharma Cash Flow Statement

Financials in millions IDR. Fiscal year is January - December.

Millions IDR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	3,685	3,667	3,502	3,837	3,030	2,116
Depreciation & Amortization	12,445	12,445	7,073	8,267	389.92	-
Other Operating Activities	-24,172	-22,566	-3,077	460.04	1,329	-2,064
Operating Cash Flow	-8,042	-6,453	7,498	12,563	4,749	52.59
Operating Cash Flow Growth	-	-	-40.32%	164.55%	8929.73%	-
Capital Expenditures	-599.13	-8,380	-36,057	-46,359	-5,591	-
Sale of Property, Plant & Equipment	-	-	6,822	-	-	-
Investing Cash Flow	5,311	-8,380	-29,235	-46,359	-5,591	-
Long-Term Debt Issued	-	30,581	29,534	9,866	669.74	-
Long-Term Debt Repaid	-	-15,692	-9,190	-	-	-
Net Debt Issued (Repaid)	2,872	14,889	20,344	9,866	669.74	-
Issuance of Common Stock	-	-	-	33,125	-	-
Common Dividends Paid	-	-	-	-7,500	-	-
Financing Cash Flow	2,872	14,889	20,344	35,491	669.74	-
Miscellaneous Cash Flow Adjustments	0	0	-	-	-	-
Net Cash Flow	141.03	55.45	-1,393	1,695	-172.33	52.59
Free Cash Flow	-8,641	-14,834	-28,559	-33,796	-842.07	52.59
Free Cash Flow Margin	-8.62%	-15.82%	-37.70%	-55.50%	-2.38%	0.18%
Free Cash Flow Per Share	-10.70	-18.84	-36.27	-49.83	-2.57	0.16
Cash Income Tax Paid	-	-	-	1,221	692.71	638.44
Levered Free Cash Flow	10,371	5,102	-27,710	-29,700	-1,558	-
Unlevered Free Cash Flow	18,203	11,567	-25,237	-29,146	-1,558	-
Change in Net Working Capital	4,738	2,195	1,591	-5,290	-1,233	-

Updated Jul 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.